Sherlock et al. [57] report results from analyses of data recorded as part of a phase 2, randomized, placebo-controlled clinical trial evaluating the myostatin inhibitor domagrozumab among 120 patients with DMD. This evidence concerns the gene MSTN and Duchenne muscular dystrophy.